Clinical Trial Search

Primary: Randomized Controlled Period: Change From Baseline in Log-Transformed Urine Protein-to-Creatinine Ratio (uPCR) at Week 26 — -1.114; 0.029 log (uPCR) — p=<0.0001

Primary: Change From Baseline In Composite Biopsy Score At Week 28 — 11.7; 9.3; 9.2; 10.7 score on a scale

Primary: Change From Baseline to Week 26 in the C3G Histologic Index for Disease Activity - Subjects With Elevated C5b-9 — -0.9; -1.0 score on a scale — p=0.9670

Primary: Change From Baseline In Serum C3 Complement Protein (C3) Levels On Day 15 — 0.32; 0.56; 0.48; 0.35 g/L

Primary: Change From Baseline in Spleen Volume Measured by MRI. — -26.91; -38.01 percentage of change — p=<0.0001

Primary: Overall Survival (OS) Time — 16.3; 14.5; 13.4 Months — p=0.0328

Primary: Percentage of Subjects With Reduction in C3c Staining on Renal Biopsy at Week 12 — 50.0; 33.3 Percentage of participants

Primary: Number of Participants With Biopsy-proven Acute Rejection at 6-months After Randomization to Induction Therapy — 31; 68 Participants — p=<0.0001

Primary: 6-Year Kaplan-Meier Estimated Cumulative Incidence Rate of Occurrence of Any Reoperation — 8.3; 31.7; 13.8; 31.3 percentage of subjects

Primary: Spleen Volume — 2324.0; 2120.0; 778.0; 1707.7 mL

Primary: Number of Participants With an Actionable Lesion on CCE vs. CTC Confirmed by Optical Colonoscopy — 34; 11 Participants

Primary: Circumferential Visualization of the Z-line — 0; 5; 5; 7 Participants

Primary: Change From Baseline in the International Knee Documentation Committee (IKDC) Subjective Knee Evaluation Score at 1 Year — 23.3; 9.9 scores on a scale — p=<0.01

Primary: Cohort A: Change From Baseline in Urine Protein to Creatinine Concentration Ratio (UPCR) — 0.55 ratio — p=0.0003

Primary: Number of Participants Meeting the Primary Outcome Defined as Any of the Below Events Occurring During the 6 Weeks Following Administration, at Least Possibly Related to…

Primary: Occurrence of All Treatment-emergent Adverse Events (TEAEs) — 8; 19; 22; 155 events

Primary: Medically Verified Cancer Genetic Risk Assessment Uptake at 6 Months — 5; 6; 32 Participants — p=<.0001

Primary: Mean Change From Baseline to Month 9 in Hemoglobin (Hgb) Concentration for Each Treatment Group. — 1.624; 1.488 gram per deciliter (g/dl)

Primary: Progression-free Survival (PFS) — 27.7; 26.4 weeks — p=0.86

Primary: Number of Participants for Which Treatment Was Concluded to be Safe — 6; 18; 4; 5 participants

Primary: Percentage of Participants With Engraftment — 100 percentage of participants

Primary: Number of Participants With Dose-limiting Toxicities (DLT) — 0 Participants

Primary: Comparison of the Responder Rates Between Two Treatment Groups in the Efficacy Period — 54.2; 20.7 percentage of responders — p=<0.001

Primary: Therapeutic Response — 40; 3; 1; 6 Participants

Primary: Number of Subjects With Procedural Technical Success — 123 Participants

Primary: Cumulative Patency — 5 Participants

Primary: The Cumulative Probability of Typical-use 6 Month (183 Days) Pregnancy. — 0.12; 0.12 6 month probability of pregnancy

Primary: Number of Participants With Adverse Events — 3; 6; 4; 3 Participants

Primary: Number of Participants Meeting the Primary Outcome Defined as Any of the Below Events Occurring During the 6 Weeks Following Administration, at Least Possibly Related to…

Primary: Overall Survival (OS) — 10.2; 11.64 months